Clinical pharmacology of intracarotid etoposide.
Pharmacokinetics studies were performed in ten patients who received VP-16 by intracarotid infusion at 100-300 mg/m2. VP-16 was analyzed by high-pressure liquid chromatography. ESTRIP and NONLIN were used to characterize VP-16 pharmacokinetics. VP-16 disappeared biphasically, with a t1/2 beta of 6.1 +/- 1.4 h; the total clearance was 26.8 +/- 2.8 ml/min/m2, and the Vss was 8.8 +/- 1.6 l/m2. The pharmacokinetics was not significantly different after administration by the IV route. However, at a lower dosage, less than 140 mg/m2, the half-life appears to be shorter. This may or may not be significant, since VP-16 pharmacokinetics is quite variable and the number of patients studied is relatively small. Overall, the brain and brain tumor do not appear to have any first-pass effect on VP-16 pharmacokinetics.
N
N
Savaraj
L G
LG
Feun
K
K
Lu
S
S
Wallace
W S
WS
Fields
T L
TL
Loo
D001921:Brain / Q000378:metabolism; D002339:Carotid Arteries; D005047:Etoposide / Q000008:administration & dosage / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D007269:Injections, Intra-Arterial; D007700:Kinetics; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D005047:Etoposide; D011034:Podophyllotoxin